Cancer statistics, 2019

CA Cancer Journal for Clinicians

Volumn 69, Issue 1, 2019, Pages 7-34

  Siegel, Rebecca L ^a   Miller, Kimberly D ^a   Jemal, Ahmedin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

cancer cases; cancer statistics; death rates; incidence; mortality

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER STATISTICS; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; ETHNICITY; FEMALE; GEOGRAPHIC DISTRIBUTION; GROUPS BY AGE; HEALTH DISPARITY; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; POVERTY; PRIORITY JOURNAL; PROBABILITY; SOCIAL STATUS; TREND STUDY; UNITED STATES; UTERINE CERVIX CANCER; VERY ELDERLY; YOUNG ADULT; ETHNIC GROUP; HEALTH CARE DISPARITY; INCIDENCE; NEOPLASM; NON PROFIT ORGANIZATION; SOCIOECONOMICS; SURVIVAL RATE;

AMERICAN CANCER SOCIETY; ETHNIC GROUPS; FEMALE; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; INCIDENCE; MALE; NEOPLASMS; SOCIOECONOMIC FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 85059687888     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21551     Document Type: Article

References (103)

1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All COD, Total US (1969–2016) -Linked To County Attributes-Total US, 1969–2016 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2018; underlying mortality data provided by National Center for Health Statistics 2018.
2. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All COD, Total US (1990–2016) -Linked To County Attributes-Total US, 1969–2016 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2018; underlying mortality data provided by National Center for Health Statistics 2018.
3. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930–1998. Cancer. 2003;97(suppl 12):3133-3275.
4. Murphy SL, Kochanek KD, Xu J, Heron M. Deaths: Final Data for 2012. National Vital Statistics Reports. Vol 63. No. 9. Hyattsville, MD: National Center for Health Statistics; 2015.
5. Copeland G, Green D, Firth R, et al. Cancer In North America, 2011–2015. Vol 3. Registry-Specific Cancer Mortality in the United States and Canada. Springfield, IL: North American Association of Central Cancer Registries Inc; 2018.
6. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data, Nov. 2017 Sub (1973–2015) -Linked To County Attributes-Total US, 1969–2016 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2018.
7. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data with Delay-Adjustment, Malignant Only, Nov. 2017 Sub (1975–2015) -Linked To County Attributes-Total US, 1969–2016 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2018.
8. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov. 2017 Sub (2000–2015) -Linked To County Attributes-Total US, 1969–2016 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2018.
9. Statistical Research and Applications Branch, National Cancer Institute. DevCan: Probability of Developing or Dying of Cancer Software. Version 6.7.6. Bethesda, MD: Surveillance Research Program, Statistical Methodology and Applications, National Cancer Institute; 2018.
10. Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2015. Bethesda, MD: National Cancer Institute; 2018.
11. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-CiNA Analytic File, 1995-2015, for Expanded Races, Custom File With County, ACS Facts and Figures Projection Project (Which Includes Data From CDC’s National Program of Cancer Registries [NPCR], CCCR’s Provincial and Territorial Registries, and the NCI’s Surveillance, Epidemiology, and End Results [SEER] Registries). Bethesda, MD: North American Association of Central Cancer Registries; 2018.
12. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-CiNA Analytic File, 1995-2015, for NHIAv2 Origin, Custom File With County, ACS Facts and Figures Projection Project (Which Includes Data From CDC’s National Program of Cancer Registries [NPCR], CCCR’s Provincial and Territorial Registries, and the NCI’s Surveillance, Epidemiology, and End Results [SEER] Registries). Bethesda, MD: North American Association of Central Cancer Registries; 2018.
13. Copeland G, Green D, Firth R, et al. Cancer in North America: 2011-2015. Vol 1. Combined Cancer Incidence for the United States, Canada and North America. Springfield, IL: North American Association of Central Cancer Registries Inc; 2018.
14. Copeland G, Green D, Firth R, et al. Cancer in North America: 2011–2015. Vol 2. Registry-Specific Cancer Incidence in the United States and Canada. Springfield, IL: North American Association of Central Cancer Registries Inc; 2018.
15. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer. 2005;103:1457-1467.
16. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
17. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Rev. Vols I-III. Geneva: World Health Organization; 2011.
18. Surveillance Research Program, National Cancer Institute. SEER*Stat Software. Version 8.3.5. Bethesda, MD: Surveillance Research Program, National Cancer Institute; 2018.
19. Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program, Version 4.6.0.1. Bethesda, MD: Statistical Research and Applications Branch, National Cancer Institute; 2018.
20. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94:1537-1545.
21. Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin. 2007;57:30-42.
22. Zhu L, Pickle LW, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence. Cancer. 2012;118:1100-1109.
23. Chen HS, Portier K, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: Part I: evaluation of temporal projection methods for mortality. Cancer. 2012;118:1091-1099.
24. Chaudry A, Wimer C, Macartney S, et al. Poverty in the United States: 50-Year Trends and Safety Net Impacts. aspe.hhs.gov/system/files/pdf/154286/50YearTrends.pdf. Accessed October 10, 2018.
25. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626-638.
26. Wiren S, Haggstrom C, Ulmer H, et al. Pooled cohort study on height and risk of cancer and cancer death. Cancer Causes Control. 2014;25:151-159.
27. Walter RB, Brasky TM, Buckley SA, Potter JD, White E. Height as an explanatory factor for sex differences in human cancer. J Natl Cancer Inst. 2013;105:860-868.
28. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
29. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
30. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134.
31. Fedewa SA, Ward EM, Brawley O, Jemal A. Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States. JAMA Intern Med. 2017;177:1040-1042.
32. Negoita S, Feuer EJ, Mariotto A, et al. Annual Report to the Nation on the Status of Cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124:2801-2814.
33. U.S. Preventive Services Task Force. Draft Recommendation Statement: Screening for Prostate Cancer. screeningforprostatecancer.org. Accessed September 27, 2017.
34. Fenton J, Weyrick M, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen–based screening for prostate cancer: a systematic evidence review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2017. AHRQ Pub. No. 17–05229-EF-1.
35. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319:1901-1913.
36. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data with Delay-Adjustment, Malignant Only, Nov. 2017 Sub (2000–2015)-Linked To County Attributes-Total US, 1969–2016 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2018.
37. Kohler BA, Sherman RL, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107:djv048.
38. Cronin KA, Lake AJ, Scott S, et al. Annual Report to the Nation on the Status of Cancer, part I: national cancer statistics. Cancer. 2018;124:2785-2800.
39. Harris JE. Cigarette smoking among successive birth cohorts of men and women in the United States during 1900–80. J Natl Cancer Inst. 1983;71:473-479.
40. Jemal A, Ma J, Rosenberg PS, Siegel R, Anderson WF. Increasing lung cancer death rates among young women in southern and midwestern states. J Clin Oncol. 2012;30:2739-2744.
41. Jemal A, Miller KD, Ma J, et al. Higher lung cancer incidence in young women than young men in the United States. N Engl J Med. 2018;378:1999-2009.
42. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573.
43. Cress RD, Morris C, Ellison GL, Goodman MT. Secular changes in colorectal cancer incidence by subsite, stage at diagnosis, and race/ethnicity, 1992–2001. Cancer. 2006;107(suppl 5):1142-1152.
44. Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992–2008. Cancer Epidemiol Biomarkers Prev. 2012;21:411-416.
45. National Center for Health Statistics, Centers for Disease Control and Prevention. National Health Interview Surveys 2000 and 2015. Public Use Data Files 2001. Atlanta, GA: National Center for Health Statistics, Centers for Disease Control and Prevention; 2016.
46. Islami F, Sauer AG, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable factors in the United States in 2014. CA Cancer J Clin. 2018;68:31-54.
47. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62:1353-1363.
48. Pawlotsky JM. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis. 2014;34:22-29.
49. Smith BD, Morgan RL, Beckett GA, et al. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61:1-32.
50. Moyer VA; US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-357.
51. Flanigan CA, Leung SJ, Rowe KA, et al. Evaluation of the impact of mandating health care providers to offer hepatitis C virus screening to all persons born during 1945–1965–New York, 2014. MMWR Morb Mortal Wkly Rep. 2017;66:1023-1026.
52. Jemal A, Fedewa SA. Recent hepatitis C virus testing patterns among baby boomers. Am J Prev Med. 2017;53:e31-e33.
53. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention. Viral hepatitis surveillance, United States, 2016. cdc.gov/hepatitis/statistics/2016surveillance/index.htm. Accessed September 30, 2018.
54. Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108:175-181.
55. Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975–2014, featuring survival. J Natl Cancer Inst. 2017;109(9).
56. Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186-e193.
57. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
58. Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States–2010 to 2015. JAMA Oncol. 2017;3:1278-1281.
59. Huo J, Shen C, Volk RJ, Shih Y. Use of CT and chest radiography for lung cancer screening before and after publication of screening guidelines: intended and unintended uptake. JAMA Intern Med. 2017;177:439-441.
60. Brenner AT, Malo TL, Margolis M, et al. Evaluating shared decision making for lung cancer screening. JAMA Intern Med. 2018;178:1311-1316.
61. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer?JAMA. 2000;283:2975-2978.
62. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175-181.
63. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167:449-455.
64. Heron M, Anderson RN. Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality. Hyattsville, MD: National Center for Health Statistics; 2016. NCHS Data Brief No. 254.
65. Siegel RL, Fedewa SA, Miller KD, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015;65:457-480.
66. Torre LA, Sauer AM, Chen MSJr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females. CA Cancer J Clin. 2016;66:182-202.
67. Jeon J, Holford TR, Levy DT, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach [published online ahead of print October 9, 2018]. Ann Intern Med. https://doi.org/10.7326/M18-1250.
68. Centers for Disease Control and Prevention (CDC). Cervical cancer screening among women aged 18-30 years–United States, 2000-2010. MMWR Morb Mortal Wkly Rep. 2013;61:1038-1042.
69. Watson M, Benard V, King J, Crawford A, Saraiya M. National assessment of HPV and Pap tests: changes in cervical cancer screening, National Health Interview Survey. Prev Med. 2017;100:243-247.
70. Egen O, Beatty K, Blackley DJ, Brown K, Wykoff R. Health and social conditions of the poorest versus wealthiest counties in the United States. Am J Public Health. 2017;107:130-135.
71. Phelan JC, Link BG, Tehranifar P. Social conditions as fundamental causes of health inequalities: theory, evidence, and policy implications. J Health Soc Behav. 2010;51(suppl):S28-S40.
72. Siegel RL, Jemal A, Wender RC, Gansler T, Ma J, Brawley OW. An assessment of progress in cancer control. CA Cancer J Clin. 2018;68:329-339.
73. Singh GK, Miller BA, Hankey BF. Changing area socioeconomic patterns in U.S. cancer mortality, 1950–1998: Part II–Lung and colorectal cancers. J Natl Cancer Inst. 2002;94:916-925.
74. Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950–2014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017;2017:2819372.
75. Boscoe FP, Johnson CJ, Sherman RL, Stinchcomb DG, Lin G, Henry KA. The relationship between area poverty rate and site-specific cancer incidence in the United States. Cancer. 2014;120:2191-2198.
76. Wang A, Clouston SA, Rubin MS, Colen CG, Link BG. Fundamental causes of colorectal cancer mortality: the implications of informational diffusion. Milbank Q. 2012;90:592-618.
77. Bennett KJ, Pumkam C, Bellinger JD, Probst JC. Cancer screening delivery in persistent poverty rural counties. J Prim Care Community Health. 2011;2:240-249.
78. Henry KA, Sherman R, Farber S, Cockburn M, Goldberg DW, Stroup AM. The joint effects of census tract poverty and geographic access on late-stage breast cancer diagnosis in 10 US states. Health Place. 2013;21:110-121.
79. Maruthappu M, Watkins J, Noor AM, et al. Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990–2010: a longitudinal analysis. Lancet. 2016;388:684-695.
80. Grubbs SS, Polite BN, Carney JJr, et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol. 2013;31:1928-1930.
81. Sommers BD, Baicker K, Epstein AM. Mortality and access to care among adults after state Medicaid expansions. N Engl J Med. 2012;367:1025-1034.
82. Sommers BD, Long SK, Baicker K. Changes in mortality after Massachusetts health care reform: a quasi-experimental study. Ann Intern Med. 2014;160:585-593.
83. Byrne MM, Halman LJ, Koniaris LG, Cassileth PA, Rosenblatt JD, Cheung MC. Effects of poverty and race on outcomes in acute myeloid leukemia. Am J Clin Oncol. 2011;34:297-304.
84. Petridou ET, Sergentanis TN, Perlepe C, et al. Socioeconomic disparities in survival from childhood leukemia in the United States and globally: a meta-analysis. Ann Oncol. 2015;26:589-597.
85. Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer. 2008;113:3231-3241.
86. Byers TE, Wolf HJ, Bauer KR, et al.: Patterns of Care Study Group. The impact of socioeconomic status on survival after cancer in the United States: findings from the National Program of Cancer Registries Patterns of Care Study. Cancer. 2008;113:582-591.
87. Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007;99:1384-1394.
88. Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev. 2005;14:590-595.
89. Khanolkar AR, Ljung R, Talback M, et al. Socioeconomic position and the risk of brain tumour: a Swedish national population-based cohort study. J Epidemiol Community Health. 2016;70:1222-1228.
90. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78-93.
91. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287:2106-2113.
92. Nelson DE, Mowery P, Asman K, et al. Long-term trends in adolescent and young adult smoking in the United States: metapatterns and implications. Am J Public Health. 2008;98:905-915.
93. Walker TY, Elam-Evans LD, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years–United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:909-917.
94. Hariri S, Bennett NM, Niccolai LM, et al. HPV-IMPACT Working Group. Reduction in HPV 16/18–associated high grade cervical lesions following HPV vaccine introduction in the United States–2008-2012. Vaccine. 2015;33:1608-1613.
95. Watson M, Soman A, Flagg EW, et al. Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009–2012. Prev Med. 2017;103:60-65.
96. Ezzati M, Friedman AB, Kulkarni SC, Murray CJ. The reversal of fortunes: trends in county mortality and cross-county mortality disparities in the United States. PLoS Medicine. 2008;5:e66.
97. Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C, et al. Trends and patterns of disparities in cancer mortality among US counties, 1980–2014. JAMA. 2017;317:388-406.
98. Siegel RL, Sahar L, Robbins A, Jemal A. Where can colorectal cancer screening interventions have the most impact?Cancer Epidemiol Biomarkers Prev. 2015;24:1151-1156.
99. Nguyen BT, Han X, Jemal A, Drope J. Diet quality, risk factors and access to care among low-income uninsured American adults in states expanding Medicaid vs. states not expanding under the Affordable Care Act. Prev Med. 2016;91:169-171.
100. Sommers BD, Gawande AA, Baicker K. Health insurance coverage and health–what the recent evidence tells us. N Engl J Med. 2017;377:586-593.
101. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100:1672-1694.
102. State Tobacco Activities Tracking and Evaluation (STATE) System, Centers for Disease Control and Prevention. Map of current cigarette use among adults: current cigarette use among adults (Behavior Risk Factor Surveillance System) 2016. cdc.gov/statesystem/cigaretteuseadult.html. Accessed October 15, 2018.
103. Kantarjian HM, Keating MJ, Freireich EJ. Toward the potential cure of leukemias in the next decade [published online ahead of print October 6, 2018]. Cancer. https://doi.org/10.1002/cncr.31669.